EMERYVILLE, Calif.,
Aug. 20, 2021 /PRNewswire/
-- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic
biotechnology company active in the Clean Health and Beauty markets
through its consumer brands, and a top supplier of sustainable and
natural ingredients, today announced promising in-vivo results in a
study of its licensed RNA vaccine through intranasal delivery,
developed in collaboration with the Infectious Disease Research
Institute (IDRI).
Current mRNA vaccine technologies are providing limited immunity
protection for the upper respiratory system. As a result,
vaccinated people may experience viral replication and viral
shedding regardless of variants.
In-vivo results indicate that, when delivered to the mucosal
membranes via intranasal administration, the Amyris/IDRI RNA
vaccine generates antibodies and provides upper respiratory
protection for SARS-CoV-2 (COVID-19), which Amyris believes has the
potential to provide fuller protection against current variants of
SARS-CoV-2. The Amyris/IDRI RNA technology may also support the
potential for intranasal vaccine delivery that can protect against
SARS-CoV-2 and other respiratory diseases, including the flu.
If approved and commercialized, the Amyris/IDRI RNA vaccine is
targeted to be more accessible to people in underserved countries.
In addition, the intranasal vaccine may offer improved upper
respiratory protection beyond currently approved
vaccines.
"Amyris is committed to developing and delivering the most
affordable and best performing protection against SARS-CoV-2 and
other respiratory diseases," commented John
Melo, President and Chief Executive Officer. "Our previously
announced collaboration with Nant
Africa, LLC is advancing to human trials in South Africa and includes them funding human
clinical trials, which upon successful completion and approval, are
expected to be followed by the production and scaling of the
vaccine in South Africa as early
as next year. With these new in-vivo results, we are exploring a
simple nasal delivery system for our RNA vaccine, which we believe
has the potential to provide much needed upper respiratory
protection against SARS-CoV-2. We are working diligently to prove
the effectiveness of our RNA technology and drive speed to
market."
Amyris will provide a detailed update of the progress of its
vaccine platform and a roadmap for scale up and delivery during one
of its upcoming investor mini-series webinars.
About Amyris
Amyris (Nasdaq: AMRS) is a science
and technology leader in the research, development and production
of sustainable ingredients for the Clean Health & Beauty and
Flavors & Fragrances markets. Amyris uses an impressive array
of exclusive technologies, including state-of-the-art machine
learning, robotics and artificial intelligence. Our ingredients are
included in over 3,000 products from the world's top brands,
reaching more than 200 million consumers. Amyris is proud to own
and operate a family of consumer brands - all built around its No
Compromise® promise of clean ingredients: Biossanceâ clean
beauty skincare, Pipetteâ clean baby skincare, and Purecane™,
a zero-calorie sweetener naturally derived from sugarcane. For more
information, please visit www.amyris.com.
Forward-Looking Statements
This release contains
forward-looking statements, and any statements other than
statements of historical fact could be deemed to be forward-looking
statements. These forward-looking statements include, among other
things, statements regarding Amyris' belief that its RNA vaccine
has the potential to provide fuller protection against current
SARS-CoV-2 variants and to support intranasal delivery of other
respiratory disease vaccines; Amyris' expectation that, if approved
and launched, its RNA vaccine, will advance to human trials in
South Africa and the timing
thereof, will be produced and scaled as early as next year, and
will improve global access to RNA vaccines. These statements are
based on management's current expectations and actual results and
future events may differ materially due to risks and uncertainties,
including risks related to delays or failures in development,
regulatory approval, production and commercialization of products;
risks related to Amyris's reliance on third parties; Amyris's
liquidity and ability to fund operating and capital expenses; and
other risks detailed from time to time in filings Amyris makes with
the Securities and Exchange Commission, including Annual Reports on
Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on
Form 8-K. Amyris disclaims any obligation to update information
contained in these forward-looking statements, whether as a result
of new information, future events, or otherwise.
Amyris, the Amyris logo, No Compromise, Biossance, Pipette, and
Purecane are trademarks or registered trademarks of Amyris, Inc. in
the U.S. and/or other countries.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/amyris-achieves-promising-in-vivo-results-for-intranasal-delivery-of-rnanlc-vaccine-301359641.html
SOURCE Amyris, Inc.